Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations
Articolo
Data di Pubblicazione:
2022
Citazione:
Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations / Tausch, Eugen; Ljungström, Viktor; Agathangelidis, Andreas; Zapatka, Marc; Scarfò, Lydia; Jebaraj, Billy Michael Chelliah; Yosifov, Deyan Y; Müller, Annika; Munugalavadla, Veerendra; Degenhardt, Jeremiah D; Ghia, Paolo; Rosenquist, Richard; Stilgenbauer, Stephan. - In: BLOOD. - ISSN 1528-0020. - 139:22(2022), pp. 3340-3344. [10.1182/blood.2021014550]
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Cell Line, Tumor; Drug Resistance, Neoplasm; Mutation; Purines; Up-Regulation; MAP Kinase Signaling System; Quinazolinones
Elenco autori:
Tausch, Eugen; Ljungström, Viktor; Agathangelidis, Andreas; Zapatka, Marc; Scarfò, Lydia; Jebaraj, Billy Michael Chelliah; Yosifov, Deyan Y; Müller, Annika; Munugalavadla, Veerendra; Degenhardt, Jeremiah D; Ghia, Paolo; Rosenquist, Richard; Stilgenbauer, Stephan
Link alla scheda completa:
Pubblicato in: